carcinoma in situ of nasopharynx

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer	Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, carcinoma in situ of hypopharynx, carcinoma in situ of nasopharynx, epithelial neoplasm, head and neck squamous cell carcinoma, hypopharynx squamous cell carcinoma, laryngeal disorder, laryngeal neoplasm, laryngeal squamous cell carcinoma, mouth disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, nasopharyngeal squamous cell carcinoma, neoplasm, oropharynx squamous cell carcinoma, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma, stomatitis	Recruiting	Phase 2	2026-08-17		NCT06532279

Clinical trials